Solutions for Long Term Care and Retail Pharmacies"With the economic challenges pharmacies are facing, they require a
partner who provides an impactful, economic and innovative generics
offering that will enable the pharmacy to improve its business," said
Russ Procopio, vice president, Generic Sales, AmerisourceBergen Drug
Corporation. "Our customers look to AmerisourceBergen to deliver a total
value-added offering that maximizes the potential profit of generics."
PRxO Generics LTC - solution for long term care pharmacies
-
The Long Term Care solution will increase customers' profits by
leveraging a formulary of generic pharmaceuticals specific to their
needs. Long term care pharmacies typically require more unit dose and
IV prescriptions. "With a commitment to the new program, long term
care pharmacies can realize a significant savings and be able to
dedicate resources to clinical and operational investments," noted
Procopio. "Customers in long term care are looking for solutions like
PRxO Generics LTC, which meets the needs of their unique patient
population."
PRxO Generics - Retail
-
For retail customers, the newer features (which will also be
offered under the long term care program) include: access to a
select number of customer preferred generics on the PRxO SELECT
formulary, which is based on the recommendations of participating PRxO
Generics members nationwide; the substitution of a secondary item at
the same value if a primary generic is out of stock and 60-day price
protection on new generic product introductions.
-
At the same time, pharmacies will be able to access the new First to
Shelf(TM) solution, which provides new product placement and price
protection, as well as auto-ship incentives. Pharmacies will be able
to improve their profitability during a generics introductory period.
"This new and expanded PRxO Generics offering is another example of
AmerisourceBergen's ongoing efforts to provide our customers with the
value solutions they need to maximize their business and serve their
patients," said Procopio.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies with operations primarily in the United States, Canada.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $71 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 10,000 people. AmerisourceBergen is ranked #26 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of laws and
regulations governing the marketing, sale and purchase of pharmaceutical
products; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; significant
breakdown or interruption of our information technology systems; our
inability to implement an enterprise resource planning (ERP) system to
handle business and financial processes within AmerisourceBergen Drug
Corporation's operations and our corporate functions without operating
problems and/or cost overruns; success of integration, restructuring or
systems initiatives; interest rate and foreign currency exchange rate
fluctuations; economic, business, competitive and/or regulatory
developments in Canada, the United Kingdom and elsewhere outside of the
United States, including potential changes in Canadian provincial
legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing or service fees; the impact of
divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our
inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax legislation or adverse
resolution of challenges to our tax positions; increased costs of
maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company's Annual Report on Form 10-K for this
Fiscal Year Ended September 30, 2009 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.
SOURCE: AmerisourceBergen
AmerisourceBergen
Nora Beger, 610-727-2384
nbeger@amerisourcebergen.com